For immunochemical detection of BCMA
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

BCMA/CD269 Polyclonal Antibody

Item No. 43761

Technical Information
Synonyms
  • B cell Maturation Antigen
  • B cell Maturation Protein
  • BCMP
  • TNF Receptor Superfamily Member 17
  • TNFRSF17
Immunogen
Recombinant human BCMA
20 or 100 µl of protein A-affinity purified polyclonal antibody
Storage Buffer
0.2 μm filtered solution in PBS
Host
Rabbit
Isotype
IgG
Applications
ELISA
Cross Reactivity
(+) BCMA
Species Reactivity
(+) Human
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    B cell maturation antigen (BCMA), also known as CD269, is a member of the TNF receptor superfamily.1 It is composed of an extracellular domain, a transmembrane region, and a cytoplasmic domain.1,2 BCMA is found in the cell membrane of late memory B cells and recognizes TNF superfamily member 13B (TNFSF13B), also known as B cell activating factor (BAFF), and a proliferation-inducing ligand (APRIL), which both promote B cell survival and differentiation into short- or long-lived plasma cells, antibody production, and immunoglobulin class switching.1,3 The extracellular domain of BCMA can cleaved by γ-secretase to release soluble BCMA (sBCMA), which can bind APRIL and prevent APRIL-induced signaling in B cells, reducing B cell survival.2 Increased sBCMA levels are associated with lower progression-free- and overall survival in patients with multiple myeloma.4 Cayman's BCMA/CD269 Polyclonal Antibody can be used for ELISA.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Cho, S.-F., Anderson, K.C., and Tai, Y.-T. Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy. Front. Immunol. 9, 1821 (2018).

    2. Laurent, S.A., Hoffmann, F.S., Kuhn, P.-H., et alγ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat. Commun. 6, 7333 (2015).

    3. Stohl, W. Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr. Metab. Immune Disord. Drug Targets 6(4), 351-358 (2006).

    4. Ghermezi, M., Li, M., Vardanyan, S., et alSerum B-cell maturation antigen: A novel biomarker to predict outcomes for multiple myeloma patients. Haematologica 102(4), 785-795 (2017).